Methoxetamine: Difference between revisions
GrimReaper (talk | contribs) No edit summary |
GrimReaper (talk | contribs) No edit summary |
||
| Line 64: | Line 64: | ||
* Out-of-body experience (less intense then ketamine) | * Out-of-body experience (less intense then ketamine) | ||
= Neutral = | == Neutral == | ||
* Distortion or loss of sensory perceptions (common) | |||
Distortion or loss of sensory perceptions (common) | * Dissociation of mind from body | ||
Dissociation of mind from body | * Sweating | ||
Sweating | * Analgesia, numbness | ||
Analgesia, numbness | * Significant change in perception of time | ||
Significant change in perception of time | * Increase in heart rate | ||
Increase in heart rate | * Confusion, disorientation | ||
Confusion, disorientation | |||
== Negative == | |||
* Risk of psychological dependency | * Risk of psychological dependency | ||
* Nasal discomfort upon insufflation | * Nasal discomfort upon insufflation | ||
| Line 87: | Line 85: | ||
* Loss of consciousness | * Loss of consciousness | ||
* Depression of heart rate and respiration (risk increases with increased dose or when combined with depressants) | * Depression of heart rate and respiration (risk increases with increased dose or when combined with depressants) | ||
= Harm Reduction = | = Harm Reduction = | ||
Revision as of 04:54, 9 July 2014
General Information
Methoxamine (3-MeO-2-Oxo-PCE) is a near chemical analogue of Ketamine and PCP. It was first publicly reported in 2010. Some say it's similar to Ketamine or a high dose DXM. Methoxetamine differs from many dissociatives such as ketamine and phencyclidine that were developed as pharmaceuticals in that it was designed for grey market distribution, making it a rare instance of a true designer drug. It has been shown to act as an NMDA receptor antagonist and unlike ketamine also acts as Serotonin Reuptake Inhibitor. The N-Ethyl group on this compound increases potency.
Dosage
Oral
Threshold: 5-20mg
Low: 10-30mg
Common: 40-60mg
Strong: 50-100mg+
Insufflated
Threshold: 5-15mg
Low: 15-30mg
Medium: 30-50mg
Strong: 50-75mg
Hole: 75-100mg+
Sublingual
Threshold: 5-10mg
Low: 10-25mg
Medium: 40-60mg
Strong: 60-75mg
Hole: 75-100mg
Duration
Oral
Onset: 30-60 minutes
Total duration: 3-6 hours
After effects (depends on dose): 2-48 hours
Insufflated
Onst: 5-20 minutes
Total duration: 3-6 hours
After effects (depends on dose): 2-48 hours
Sublingual
Onset: 15-45 minutes
Total duration: 3-6 hours
After effects (depends on dose): 2-48 hours
Effects
Positive
- Euphoria, mood lift
- Sense of calm and serenity
- Vivid recall of past memories and dreams
- Closed- and open-eye visuals (common)
- Out-of-body experience (less intense then ketamine)
Neutral
- Distortion or loss of sensory perceptions (common)
- Dissociation of mind from body
- Sweating
- Analgesia, numbness
- Significant change in perception of time
- Increase in heart rate
- Confusion, disorientation
Negative
- Risk of psychological dependency
- Nasal discomfort upon insufflation
- Blacking out and forgetting one has taken a drug
- Discomfort, pain or numbness at injection site (with IM)
- Severe confusion, disorganised thinking
- Vertigo, spinning sensation (risk of injury)
- Nausea, vomiting
- Susceptibility to accidents (from uncoordination and change in perception of body and time)
- Severe dissociation, depersonalisation
- Loss of consciousness
- Depression of heart rate and respiration (risk increases with increased dose or when combined with depressants)
Harm Reduction
- Avoid driving at all costs.
- Avoid walking or moving around in general if you are on a medium to hole dose.
- Taking this on a non-empty substance could lead to nausea.